Try reading people!
WR = wedge resection
WRB = WR plus brachytherapy
SBRT = stereotactic body radiation therapy
Local control (LC) was SIMILAR in the three groups (p = 0.60) (p value needs to be lower):
92.2% for WR
96.2% for WR+Cs-131
95.5% for SBRT .
Five-year overall survival was similar to WR (p = 0.02):
100% in the WR+B group
97.7% in the WR group
89.6% in the SBRT group
Was similar in the three groups.
Analysis of stereotactic radiation vs. wedge resection vs. wedge resection plus Cesium-131 brachytherapy in early-stage lung cancer. Bhupesh Parashar et al., 2015. (Brachyjournal)
Agreed, I think Chugai feels they paid $10 million and now have the upper hand.
They are going to hold Gil's feet to the fire. But, in the end, are they going to give Multistem a second chance in some way?
This is why small biotechs often generate the new technology.
They are often the smartest people in the room and do not have to deal with loud voices and poliitcs.
Lets see if Chugai can make a decision without loud voices and politics.
An alternative hypothesis is that Pfizer wanted to taint stem cells for UC to promote their own small molecule.
Pfizer Key Programs Registration / Phase 3
Xeljanz® (tofacitinib) – Ulcerative Colitis
Regardless, Pfizer designed the Multistem UC trial to fail because they knew Osiris required 4+ doses of Prochymal to provide therapeutic value.
Any way you cut it, Pfizer used Multistem with wreckless disregard for patients, and I am going on the record with this one. This study was beyond a reasonable long shot. One dose to treat patients is not responsible or fair to the patient. There is no excsure for this, especially without a multi dose followup option. Shame on Pfizer!
Sayhay66.....Cleveland (sigh)...bad attitude...distracted
They will chop shop the IP and stroke opportunity and throw the rest in Cuyahoga River on their way out of town.
LOL. You agree with 50% of what I say.
Athersys could make you rich, but it could also make you broke.
Athersys could merge for $6PPS, or it could become the next Genentech.
Multistem early infusion is effective, or Gil cherry picked the numbers.
Athersys extended to 48 hrs one month after starting the trial in 2011 because the infusion staff goes home at 5PM. Athersys messed up and Edison points out that late infusion probably will not work and it didn't.
Further, in August, 2007, Icagen entered into a collaboration with Pfizer for the discovery and development of novel pharmaceuticals directed against three sodium channel targets. The success of this collaboration led to the acquisition of Icagen by Pfizer in October, 2011. Icagen’s name was subsequently changed to Neusentis in early 2012. The talented Icagen scientists are now enabling the Neusentis Ion Channel portfolio.
A shell corporation is a company which serves as a vehicle for business transactions without itself having any significant assets or operations. Some shell companies may have had operations, but those may have shrunk due to unfavorable market conditions or company mismanagement. Shell corporations are not in themselves illegal, and they do have legitimate business purposes. However, they are a main component of the underground economy, especially those based in tax havens.
As of June 08, 2007, BTHC VI, Inc. was acquired by Athersys, Inc., in a reverse merger transaction. BTHC VI, Inc. is a shell company. The company was incorporated in 2005 and is based in As of June 08, 2007, BTHC VI, Inc. was acquired by Athersys, Inc., in a reverse merger transaction. BTHC VI, Inc. is a shell company. The company was incorporated in 2005 and is based in Argyle, Texas...Population: 3,561 (2013)
On May 24, 2007, BTHC VI, Inc., a Delaware corporation, and its wholly owned subsidiary, B-VI Acquisition Corp., a Delaware corporation, entered into an Agreement and Plan of Merger with Athersys, Inc., a Delaware corporation and privately-held company. Pursuant to the terms of the Agreement and Plan of Merger, B-VI Acquisition Corp., which BTHC VI recently had incorporated in the state of Delaware for the purpose of completing the merger transaction, merged with and into Athersys on June 8, 2007, with Athersys continuing as the surviving entity in the merger. As a result of the merger, Athersys became our wholly-owned subsidiary and the business of Athersys became our sole operations. On August 31, 2007, Athersys, Inc. changed its name to ABT Holding Company, and BTHC VI, Inc. changed its name to Athersys, Inc. In June 2007, we also completed an offering of our Common Stock in a private placement. As a result, 2007 was a year of transition for us in terms of our compensation and benefit programs.
Chugai will gamble Multistem works at early time window and take Athersys for peanuts.
This is just like the Icagen-Pfizer deal.
NEW YORK, N.Y., October 28 - Pfizer Inc. (NYSE: PFE) announced
today that it has completed its acquisition of Icagen, Inc.,
through the merger of its wholly owned subsidiary, Eclipse
Acquisition Corp., with and into Icagen. Icagen is now a whollyowned
subsidiary of Pfizer. Under the terms of the transaction,
each issued and outstanding share of Icagen common stock has been
converted into the right to receive $6.00 in cash, without
interest thereon, and less any applicable withholding and